0001209191-23-033780.txt : 20230602
0001209191-23-033780.hdr.sgml : 20230602
20230602163129
ACCESSION NUMBER: 0001209191-23-033780
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230531
FILED AS OF DATE: 20230602
DATE AS OF CHANGE: 20230602
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Simson Jake
CENTRAL INDEX KEY: 0001863094
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40800
FILM NUMBER: 23989385
MAIL ADDRESS:
STREET 1: C/O JANUX THERAPEUTICS, INC.
STREET 2: 11099 N. TORREY PINES ROAD, SUITE 290
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tyra Biosciences, Inc.
CENTRAL INDEX KEY: 0001863127
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831476348
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2656 STATE STREET
CITY: CARLSBAD
STATE: CA
ZIP: 92008
BUSINESS PHONE: (619) 728-4760
MAIL ADDRESS:
STREET 1: 2656 STATE STREET
CITY: CARLSBAD
STATE: CA
ZIP: 92008
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-31
0
0001863127
Tyra Biosciences, Inc.
TYRA
0001863094
Simson Jake
C/O TYRA BIOSCIENCES, INC.
2656 STATE STREET
CARLSBAD
CA
92008
1
0
0
0
0
Stock Option (Right to Buy)
14.47
2023-05-31
4
A
0
14500
0.00
A
2033-05-30
Common Stock
14500
14500
D
The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
/s/ Ali D. Fawaz, Attorney-in-Fact
2023-06-02